Merck stock extends record run as intismeran trial boosts Keytruda growth story
Published on 08/26/2026 at 07:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) stock has pushed to record territory in August 2026 as investors digest pivotal melanoma trial results for the personalized mRNA therapy intismeran autogene in combination with the immunotherapy Keytruda.
According to a detailed market overview dated August 25, 2026, Merck shares recently closed at $156.45, up 3.8% on the day, with a 52-week trading range of $77.58 to $156.92 that underlines how far the stock has run over the past year. The Merck performance and valuation snapshot also notes that this price stands well above an intrinsic value estimate of $119.94.
Intismeran and Keytruda deliver Phase 3 melanoma win
The main catalyst for Merck in August 2026 is topline Phase 3 data from the INTerpath-001 study, which evaluated intismeran autogene, an individualized mRNA-based cancer therapy, combined with Keytruda in patients with resected high-risk melanoma.
A clinical-trial summary dated August 26, 2026 reports that the trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma and that the combination of intismeran and Keytruda reduced the risk of melanoma recurrence and distant metastasis compared with Keytruda alone, meeting both its primary and key secondary endpoints for recurrence-free survival and distant-metastasis-free survival. An overview of the personalized mRNA melanoma results emphasizes that no new safety concerns emerged in the announcement and that overall-survival data are still being followed.
An equity-market recap from August 19, 2026 notes that Merck stock jumped 12.6% to a record $152.20 on the day that the INTerpath-001 results were announced, underscoring how strongly investors reacted to the validation of intismeran plus Keytruda in high-risk melanoma. A report on the Merck share reaction highlights that the companies did not yet disclose detailed effect sizes or overall-survival outcomes, which leaves room for further data-driven moves in the stock.
Stock performance and valuation context
Beyond the single-day spike, Merck stock has delivered strong multi-week gains in the run-up and aftermath of the melanoma news. A performance analysis dated August 25, 2026 points out that Merck stock gained 45% year to date to reach $156 and advanced 19% over the prior month to $155.99, outpacing a key biotechnology exchange-traded fund that rose 15% over the same period to $216.16.
The same valuation snapshot describes Merck at $156.45 compared with a GF Value estimate of $119.94, implying that the shares trade 30.4% above that intrinsic value metric. This valuation comparison suggests that investors are already pricing in a sizable contribution from the intismeran collaboration and extended growth for Keytruda, even before detailed survival data are available.
Short-term trading dynamics reflect continued enthusiasm. A US-session recap dated August 26, 2026 notes that Merck gained 3.88% in the latest trading session alongside a double-digit rise in Moderna shares following further positive commentary on the melanoma vaccine program. The US market recap underlines that Merck is participating in a broader healthcare rally driven by clinical-trial successes.
In addition to price action, analysts have responded with higher expectations. A stock-highlights piece dated August 26, 2026 reports that Merck shares reached a fresh annual high of $156.92 and notes that analysts raised price targets on the company after the INTerpath-001 data, including one call lifting the target to $180 from $155 with an Outperform stance, signaling increased confidence that the melanoma results can support Merck's long-term growth story.
Fundamental backdrop and growth runway
While the latest same-day sources focus on the melanoma trial and share-price reaction rather than full quarterly numbers, they collectively frame the fundamental narrative around the durability of Merck's oncology franchise and the potential incremental contribution from intismeran.
Keytruda has been described in recent analyses as a standard of care in melanoma since its introduction, with long-term follow-up data demonstrating improved survival and reduced recurrence in a range of high-risk settings. A healthcare commentary on the cancer vaccine program stresses that adding intismeran to Keytruda lengthened the time before melanoma returned or new tumors appeared elsewhere, and that five-year data from a smaller study showed a 49% reduction in melanoma recurrence or metastasis compared with Keytruda alone.
The personalized mRNA approach targets neoantigens specific to each patient's tumor, and the INTerpath-001 results indicate that this strategy can materially improve recurrence-free and distant-metastasis-free survival on top of an already effective checkpoint inhibitor. The clinical-trial context for personalized mRNA vaccines cautions that overall-survival outcomes and broader indications remain to be proven, but it positions the melanoma data as an important milestone for personalized oncology.
For Merck, the partnership highlights a potential new growth leg beyond its existing Keytruda indications. A stock-valuation article dated August 25, 2026 notes that Merck's strong share-price run reflects expectations that oncology revenue will continue to expand, supported by both Keytruda's established use and emerging combinations such as intismeran. At the same time, the 30.4% premium to one intrinsic-value estimate underscores that investors are paying up for this pipeline and may require continued positive data and regulatory progress to justify the current valuation.
Market commentary also points out that while recurrence-free and distant-metastasis-free survival are important endpoints, the absence of mature overall-survival data means the long-term benefit is not fully quantified yet. Detailed hazard ratios and subgroup analyses from INTerpath-001 could either reinforce or temper the current optimism, making upcoming data presentations and regulatory interactions critical milestones for Merck's oncology story.
Intismeran and Keytruda as a representative product combination
A representative product combination at the center of Merck's current catalyst is Keytruda used alongside intismeran in high-risk melanoma following surgical resection.
Keytruda, an immune checkpoint inhibitor targeting the PD-1 pathway, is administered intravenously to help the immune system recognize and attack cancer cells. Intismeran autogene is a personalized mRNA-based therapy designed to encode multiple neoantigens identified from each patient's tumor, delivering instructions that prompt cells to produce these neoantigen fragments, which the immune system can then learn to recognize and target.
Clinical-trial summaries from August 2026 describe how patients in INTerpath-001 received both Keytruda and intismeran after surgery, with the combination leading to statistically significant improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, and no new safety signals observed in the topline data. A detailed explanation of the mechanism and clinical role notes that the trial enrolled 1,137 patients, providing a sizable dataset for assessing the benefits of adding a personalized cancer vaccine to standard immunotherapy.
The intismeran plus Keytruda regimen remains in the clinical-development stage, with regulatory submissions expected to depend on fuller data packages including survival outcomes and safety details. However, the August 19, 2026 announcement of Phase 3 success has already influenced expectations for Merck's future oncology revenue and contributed to the current strength of Merck stock.
Merck stock price and investor takeaway
In the latest trading data as of August 25, 2026, Merck stock was quoted at $156.45, within cents of its 52-week high of $156.92 and up 3.8% on the session, while sitting 45% above its level at the start of the year and 19% higher than a month earlier.
These figures place Merck stock among the stronger performers in large-cap healthcare over that period and frame the current valuation debate: investors have clearly rewarded the company for the intismeran melanoma win and the extended growth runway for Keytruda, but the shares now trade roughly 30% above one widely cited intrinsic-value estimate, suggesting that future data and commercialization steps will be closely watched to see whether the fundamentals continue to justify the premium.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Price (as of August 25, 2026, session close): $156.45 USD
Market cap: Not stated in the cited same-day sources
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: S&P 500
